Chengdu Olymvax Biopharmaceuticals Inc. (688319.SS)
CNY 15.77
(0.9%)
CNY 15.77
(0.9%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -124.46 Million CNY | 7.94% |
| 2022 | -135.19 Million CNY | 37.44% |
| 2021 | -216.11 Million CNY | -173.62% |
| 2020 | -78.98 Million CNY | 12.84% |
| 2019 | -90.61 Million CNY | -1161.44% |
| 2018 | 8.53 Million CNY | 231.72% |
| 2017 | -6.48 Million CNY | -62.55% |
| 2016 | -3.98 Million CNY | 93.0% |
| 2015 | -56.95 Million CNY | -225.34% |
| 2014 | 45.43 Million CNY | 63.78% |
| 2013 | 27.74 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 121.79 Million CNY | 1117.42% |
| 2024 Q3 | 184.91 Million CNY | -11.92% |
| 2024 Q1 | 10 Million CNY | 108.04% |
| 2023 Q1 | -169.84 Million CNY | -25.63% |
| 2023 Q3 | -166.3 Million CNY | -57.1% |
| 2023 Q2 | -105.86 Million CNY | 37.67% |
| 2023 Q4 | -124.46 Million CNY | 25.16% |
| 2023 FY | -124.46 Million CNY | 7.94% |
| 2022 Q3 | -201.37 Million CNY | 36.4% |
| 2022 Q1 | -106.65 Million CNY | 50.65% |
| 2022 FY | -135.19 Million CNY | 37.44% |
| 2022 Q4 | -135.19 Million CNY | 32.86% |
| 2022 Q2 | -316.61 Million CNY | -196.87% |
| 2021 Q3 | -122.92 Million CNY | 70.64% |
| 2021 FY | -216.11 Million CNY | -173.62% |
| 2021 Q4 | -216.11 Million CNY | -75.81% |
| 2021 Q2 | -418.69 Million CNY | -798.34% |
| 2021 Q1 | -46.6 Million CNY | 40.99% |
| 2020 Q4 | -78.98 Million CNY | 0.0% |
| 2020 FY | -78.98 Million CNY | 12.84% |
| 2020 Q1 | 95.61 Million CNY | 205.52% |
| 2020 Q2 | -50.16 Million CNY | -152.46% |
| 2020 Q3 | - CNY | 100.0% |
| 2019 FY | -90.61 Million CNY | -1161.44% |
| 2019 Q4 | -90.61 Million CNY | 0.0% |
| 2018 FY | 8.53 Million CNY | 231.72% |
| 2018 Q2 | -10.1 Million CNY | 0.0% |
| 2018 Q1 | -10.1 Million CNY | -55.95% |
| 2017 Q1 | -12.65 Million CNY | -217.45% |
| 2017 FY | -6.48 Million CNY | -62.55% |
| 2017 Q4 | -6.48 Million CNY | 0.0% |
| 2017 Q3 | -6.48 Million CNY | 48.79% |
| 2017 Q2 | -12.65 Million CNY | 0.0% |
| 2016 Q4 | -3.98 Million CNY | 0.0% |
| 2016 Q3 | -3.98 Million CNY | 0.0% |
| 2016 Q1 | 56.95 Million CNY | 328.25% |
| 2016 FY | -3.98 Million CNY | 93.0% |
| 2015 Q3 | -24.95 Million CNY | 0.0% |
| 2015 FY | -56.95 Million CNY | -225.34% |
| 2015 Q1 | 2.38 Million CNY | 0.0% |
| 2015 Q4 | -24.95 Million CNY | 0.0% |
| 2014 FY | 45.43 Million CNY | 63.78% |
| 2013 FY | 27.74 Million CNY | 0.0% |